Cargando…

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules

The programmed cell death ligand protein 1 (PD-L1) is a member of the B7 protein family and consists of 290 amino acid residues. The blockade of the PD-1/PD-L1 immune checkpoint pathway is effective in tumor treatment. Results: Two pharmacophore models were generated based on peptides and small mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Yanwen, Li, Xuanyi, Yao, Hequan, Lin, Kejiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572691/ https://www.ncbi.nlm.nih.gov/pubmed/31137573 http://dx.doi.org/10.3390/molecules24101940

Ejemplares similares

Chemical space exploration based on recurrent neural networks: applications in discovering kinase inhibitors
por: Li, Xuanyi, et al.
Publicado: (2020)

GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47
por: Shan, Wenying, et al.
Publicado: (2023)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
por: Guzik, Katarzyna, et al.
Publicado: (2019)

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
por: Ganesan, Aravindhan, et al.
Publicado: (2019)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export
por: Chen, Fang-Fang, et al.
Publicado: (2020)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
por: Zhang, Hongbo, et al.
Publicado: (2021)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
por: Liu, Chang, et al.
Publicado: (2021)

Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation
por: Liang, Jianhuai, et al.
Publicado: (2023)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
por: Acúrcio, Rita C., et al.
Publicado: (2022)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents
por: Ofori, Samuel, et al.
Publicado: (2019)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
por: Wang, Fengling, et al.
Publicado: (2023)

Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship
por: Shi, Danfeng, et al.
Publicado: (2019)

Small‐Molecule and Peptide Inhibitors of the Pro‐Survival Protein Mcl‐1
por: Beekman, Andrew M., et al.
Publicado: (2015)

YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
por: Lai, Fangfang, et al.
Publicado: (2022)

Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
por: Weng, Yi Ming, et al.
Publicado: (2018)

Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment
por: Cheng, Binbin, et al.
Publicado: (2023)

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
por: Sullivan, Kathleen M. C., et al.
Publicado: (2023)

Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments
por: Kitel, Radoslaw, et al.
Publicado: (2022)

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
por: Zak, Krzysztof M., et al.
Publicado: (2016)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
por: Yu, Lian, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors
por: Almahmoud, Suliman, et al.
Publicado: (2019)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein–protein interaction
por: Miao, Qi, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kir36qf5bfidv560bevgnktrn7